Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | MAPT | P10636 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | TP53 | P04637 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 9/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | MPC2 | O95563 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciglitazone SCHEMBL38185 | 0.99 | HPGD (1.00) | HPGDCYP3A4MAPTMEN1ALDH1A1 | |
| Ciglitazone SCHEMBL20125581 | 0.99 | HPGD (1.00) | HPGDCYP3A4MAPTMEN1ALDH1A1 | |
| Ciglitazone SCHEMBL20125576 | 0.99 | HPGD (1.00) | HPGDCYP3A4MAPTMEN1ALDH1A1 | |
| Ciglitazone SCHEMBL21582134 | 0.98 | HPGD (0.98) | HPGDCYP3A4MAPTMEN1ALDH1A1 | |
| Ciglitazone SCHEMBL8498957 | 0.93 | HPGD (0.89) | HPGDCYP3A4MAPTMEN1ALDH1A1 | |
| Ciglitazone SCHEMBL6203612 | 0.91 | HPGD (0.84) | HPGDCYP3A4MAPTMEN1ALDH1A1 | |
| SCHEMBL11091437 | 0.88 | CYP3A4 (0.81) | HPGDCYP3A4MAPTMEN1ALDH1A1 | |
| SCHEMBL12521714 | 0.87 | HPGD (0.79) | HPGDCYP3A4MAPTMEN1ALDH1A1 | |
| SCHEMBL11088249 | 0.87 | CYP3A4 (0.79) | HPGDCYP3A4MAPTMEN1ALDH1A1 | |
| SCHEMBL11083961 | 0.87 | CYP3A4 (0.78) | HPGDCYP3A4MAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022600-A1 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOUS SYSTEM TUMORS | LANDRETH GARY E | 2010-01-28 | — | — | US | disclosed |
| WO-2008070230-A2 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOS SYSTEM TUMORS | CASE WESTERN RESERVE UNIVERSITY (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022600-A1 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOUS SYSTEM TUMORS | PPARG, PPARA, FABP7 | HPGD 660/4885CYP3A4 2532/4885MAPT 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.